Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Both outcomes are clinically meaningful, but they illustrate why BMI at treatment initiation shapes expectations about results
Increased competition : Even with new medications expected to launch in the coming years, based on the prices of currently marketed products, it is unlikely that brand product pricing will decrease significantly in the next several years
Verify 7 - State availability
Key takeaways TRIUMPH-4 is the first successful Phase 3 readout for retatrutide, reporting 28.7% mean body-weight reduction at 68 weeks on the 12 mg weekly dose (26.4% on 9 mg, 2.1% on placebo)
Emerging evidence also suggests the potential to lower cardiovascular risks, highlighting its role in diabetes management (Epelde 2024
US$ 29.74
US$ 21.75
US$ 27.64
US$ 28.51
US$ 23.30
